North Carolina Wants to ‘Lead the Nation’ in Psychedelics. Here’s 1 ‘Strong Buy’ Stock to Buy Now.

Atai’s pipeline is designed to transform mental health care. Key assets include VLS-01 (DMT-based for treatment-resistant depression), EMP-01 (MDMA-based for social anxiety), and novel non-hallucinogenic 5-HT2A receptor agonists. With convenient administration methods and short in-clinic times, Atai is positioning itself as a market leader in next-gen psychedelic medicine.Based in both Berlin, Germany and the Netherlands, Atai Life Sciences is pushing the boundaries of mental health treatment. This clinical ...